Using Mnova Screen to Process, Analyze and Report Ligand-Protein Binding Spectra for Fragment-based Lead Design

Significance of the Topic

Fragment-based drug design relies on identifying weak millimolar to micromolar binders using NMR screening. Automating this analysis accelerates lead generation and enhances reproducibility in early drug discovery pipelines.

Objectives and Overview of the Study

This work introduces Mnova Screen, a plugin within the Mnova software suite, designed to process, analyze, and report NMR-based ligand–protein binding spectra. The aim is to streamline fragment-based lead design workflows by enabling high-throughput screening using 1D and 2D NMR experiments.

Methodology and Instrumentation

• Screened experiments: Saturation Transfer Difference (STD), relaxation editing (T1ρ/CPMG), WaterLOGSY and 1H–15N HSQC.
• Data formats: Raw or processed data from Bruker, Varian/Agilent, JEOL and JCAMP.
• Data organization: Flexible folder and file naming conventions or definition files to pair mixture and reference spectra.
• Peak processing: Automated baseline correction, Global Spectral Deconvolution (GSD) for peak picking and match tolerance based on reference peak width.
• Hit criteria: Percentage of matched reference peaks, intensity change thresholds, and competition tests to discriminate specific binders.

Used Instrumentation

• Mnova NMR platform with plugins: Screen, NMRPredict Desktop, qNMR, DB, Verify, Reaction Monitor and Scripting.
• Processing templates for automated phasing, baseline correction and normalization.
• Log files and stacked spectra tables for result inspection.

Main Results and Discussion

Mnova Screen successfully batches and collates diverse NMR datasets, aligns spectra via reference peaks, and applies customized normalization to identify fragment hits. The software distinguishes true binders by applying sequential filters: initial peak presence in scout spectra, followed by STD or T1ρ intensity change analysis, and final competition tests to confirm specificity. Interactive stacked-spectra viewers and editable result tables facilitate efficient manual review.

Benefits and Practical Applications

• High-throughput and standardized processing of NMR screening datasets.
• Reduced manual intervention through automated peak deconvolution and matching.
• Integrated reporting in Mnova files and spreadsheets for QA/QC, medicinal chemistry and project tracking.
• Support for multiple nuclei (1H, 19F) and experiment types within a unified workflow.

Future Trends and Possibilities for Use

Integration with machine learning for pattern recognition, cloud-based data management for collaborative screening, extension to metabolomics and reaction kinetics, and interfacing with other analytical platforms (LC/MS, GC/MS) to build multimodal screening workflows.

Conclusion

Mnova Screen addresses key bottlenecks in fragment-based lead discovery by providing a comprehensive, configurable, and automated solution for NMR ligand–protein binding analysis, thereby improving throughput, consistency and data quality in drug discovery campaigns.

References

• Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 1996;274(5292):1531–1534.
• Fejzo JF, Lepre CA, Peng JW, Bemis GW, Ajay MA, Moore JM. Chem Biol. 1999;6(10):755–769.
• Dalvit C, Pevarello P, Tato M, Veronesi M, Vulpetti A, Sundstrom M. J Biomol NMR. 2000;18(1):65–68.
• Coles M, Heller M, Kessler H. Drug Discov Today. 2003;8(17):803–810.